New Frontiers for Progress: Catalyzing Breakthroughs

Thank you to everyone who joined us in Amsterdam on Saturday, 27 September 2025 for our 4th annual OSIC Member Meeting & AI/Biomarker Innovation Showcase.

If you weren’t able to attend our Member Meeting & AI/Biomarker Innovation Showcase, or if you would like to revisit any of the sessions, a full recording is now available.

REGISTER TO WATCH

Highlights from the collaborative forum

This year’s meeting, chaired by Dr. Kevin Brown of National Jewish Health, was a day filled with bold ideas, breakthrough thinking, insightful presentations, and collaborative discussions — all focused on shaping the future of lung disease research.

The agenda highlighted key opportunities for progress — from bronchiectasis as a promising new therapeutic frontier to advancing sarcoidosis understanding through global registries and AI. Attendees learned about innovative imaging techniques like Optical Coherence Tomography (OCT) and gained insights from world-leading experts in generative AI, predictive modeling, and interpretability. The event closed with inspiring success stories from OSIC members who are turning data into discovery.

Our Panel Discussion Thought Leaders​ and Event Presenters

Bronchiectasis: A New Therapeutic Frontier
From Orphan Finding to Frontline Target

  • Panelists
Dr. Kevin Brown
Dr. Kevin Brown Chair, Department of Medicine
National Jewish Health (NJH)
Pulmonology Lead, OSIC
Dr. Helmut Prosch
Dr. Helmut Prosch Department of Biomedical Imaging and Image-guided Therapy
Medical University of Vienna
Prof. Luca Richeldi
Prof. Luca Richeldi Complex Operational Unit of Pulmonology
Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart
  • Discussion Points
  • Rising Global Prevalence & Burden: Why bronchiectasis is increasingly being recognized as a significant public health issue because of unmet need and the decline in quality of life

  • Phenotyping & Endotyping Advances: Connecting imaging features with clinical subgroups to enable precision medicine approaches

  • Overlap with Other Diseases: When bronchiectasis coexists with COPD, asthma, ILD, or post-infectious fibrosis

  • AI & Quantification Opportunities: Automating airway measurements, mucus plugging scoring, and progression tracking

  • Collaboration Call-to-Action: How OSIC members (pharma, machine learners, clinicians) can build a shared bronchiectasis resource
REGISTER TO WATCH

Sarcoidosis: From Complexity to Clarity?

  • Presenter
Elise Hoover
Elise Hoover Vice President of Research
Foundation for Sarcoidosis Research (FSR)
  • Discussion Points
  • The Challenge: Sarcoidosis is complex, heterogeneous, and historically understudied.

  • FSR’s Leadership: U.S. patient registry and partnership with OSIC; international registry planned for the future

  • AI/ML Opportunities: Predicting progression, phenotyping multi-organ involvement, identifying novel biomarkers

  • Engagement Opportunity: Inviting pharma and researchers to collaborate on future sarcoid AI initiatives

Showcase Presentation: Generative AI in Action

  • Presenter
Prof. David Barber
Prof. David Barber Global leader in probabilistic AI and foremost expert in Bayesian deep learning and Generative AI
University College London (UCL), OSIC Computational Science Lead
  • Discussion Points
  • Predictive power: Could interpretable survival models predict disease progression and patient outcomes than traditional methods?

  • Interpretability at the core: Attention maps that show which lung regions drive predictions, helping clinicians trust results

  • Cross-disease potential: Can be applied across fibrotic ILDs, bronchiectasis, and post-COVID fibrosis to build a multi-disease model

Beyond CT: How Optical Coherence Tomography Unlocks Microstructural Insight into Fibrosis

  • Presenter
Dr. Lida Hariri
Dr. Lida Hariri Associate Professor of Pathology
Massachusetts General Hospital (MGH)
  • Discussion Points
  • Visualize healthy and diseased airway and lung microstructure in vivo over large volumes (as a form of vivo microscopy)

  • Diagnose early lung disease at a microscopic level without needing invasive surgical biopsies

  • Quantitatively measure changes over disease progression and therapy on a microscopic level

  • Provide rich, quantitative data that could feed AI models for disease phenotyping and outcome prediction

  • Can be used to diagnose and characterize many lung diseases, including fibrotic ILDs, COPD, small airways disease, bronchiectasis, and post-COVID fibrosis

Unlocking Innovation: Exploring New Features and Advanced Filters in the OSIC Cloud

  • Presenter
Sandra Stapleton
Sandra Stapleton Chief Operating Officer
VIDA Diagnostics
  • Discussion Points
  • Overview of the latest enhancements to the OSIC Cloud platform, and how these features streamline data access and accelerate research workflows

  • Demonstration of how new imaging filters and views, including tMPR and subpleural views, improve data visualization and analysis

  • Exploration of the new collaboration tool designed for private cohort development

  • Presentation of the live analytics dashboard for real-time insights

Turning Data Into Discovery:
The Achievements of OSIC Members with the OSIC Cloud’s Powerful Data

SEPI-IA: A Spanish, Publicly Funded Research Initiative

  • Presenter
Carlos Illana Alejandro
Carlos Illana Alejandro Head of Advanced Health Products, PRO, Secure eSolutions
GMV
  • Discussion Points
  • What are the objectives of SEPI-IA?

  • Who is the team behind SEPI-IA?

AI-Based Quantification of Airway Diseases: From Comprehensive Characterization to Phenotyping and Progression Tracking

  • Presenter
Dr. Jean-Paul Charbonnier
Dr. Jean-Paul Charbonnier Chief Innovation Officer
Thirona
  • Discussion Points
  • How can AI-based quantification of airway wall thickening, mucus plugging, and bronchiectasis provide meaningful patient phenotypes?

  • Could longitudinal tracking of AI-based airway quantification provide more precise disease trajectory assessment?

  • What value does this bring to patient stratification and measuring treatment response?

From core lab to clinic: improving patient care with AI imaging biomarkers

  • Presenter
Dr. George Harston
Dr. George Harston Chief Medical and Innovation Officer
Brainomix
  • Discussion Points
  • Validation of algorithm performance and generalisability

     

  • Demonstration of value and maximising impact

     

  • Patient impact through clinical development and clinical adoption

When virtual OSIC database becomes virtuOSIC

  • Presenter
Dr. Ryoungwoo Jang
Dr. Ryoungwoo Jang Clinical Research Lead
Coreline Soft
  • Discussion Points
  • The OSIC database was instrumental in developing an estimated FVC (eFVC) metric that can be calculated from chest HRCT scans.

  • eFVC mimics real FVC measurements, demonstrating a high correlation validated in the separate cohort.

     

  • eFVC shows promise as a tool for monitoring disease status, predicting progression, and assessing response to pharmaceutical treatments.

Thank you to everyone who joined us in Amsterdam on Saturday, 27 September 2025 for our 4th annual OSIC Member Meeting & AI/Biomarker Innovation Showcase.

If you weren’t able to attend — or would like to revisit any of the sessions — a full recording is now available.

Watch the Member Meeting Recording

Share your details below to access the full video.